5-Azacitidine

DRUG13 trials

Conditions

AMLAcute Myeloid LeukemiaCMMLCerebral PalsyChronic Myelomonocytic LeukemiaHigh-risk Myelodysplastic SyndromeLeukemiaLymphoma, T-Cell

Phase 1

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

CompletedNCT00766116

University of California, San DiegoAcute Myeloid Leukemia

Start: 2005-07-31End: 2014-09-26Updated: 2019-02-18

Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

CompletedNCT01828346

TetraLogic PharmaceuticalsMyelodysplastic Syndrome

Start: 2013-06-30End: 2015-11-30Updated: 2016-04-21

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

RecruitingNCT03161223

University of VirginiaLymphoma, T-Cell

Start: 2018-05-30End: 2023-02-28Target: 148Updated: 2022-03-31

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

TerminatedNCT03614728

GlaxoSmithKlineNeoplasms

Start: 2018-10-16End: 2022-01-11Updated: 2023-02-06

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

RecruitingNCT04358393

Ascentage Pharma Group Inc.Acute Myeloid Leukemia, AML, Chronic Myelomonocytic Leukemia +4

Start: 2020-12-04End: 2025-12-30Target: 69Updated: 2024-02-01

Phase 2

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

CompletedNCT00795548

Heinrich-Heine University, DuesseldorfAcute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2008-11-30End: 2011-08-31Updated: 2012-01-23

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

CompletedNCT01350947

University of UtahChronic Myelomonocytic Leukemia

Start: 2011-04-30End: 2014-09-30Updated: 2016-06-13

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

TerminatedNCT02469415

M.D. Anderson Cancer CenterLeukemia

Start: 2015-09-30End: 2017-06-03Updated: 2018-10-16

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

CompletedNCT03572387

Icahn School of Medicine at Mount SinaiProstate Cancer, Prostate Neoplasms, Prostatic Neoplasms

Start: 2018-08-20End: 2022-07-08Updated: 2024-04-30

Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy

Not yet recruitingNCT07434492

Shirley Ryan AbilityLabCerebral Palsy

Start: 2026-03-01End: 2030-08-31Target: 60Updated: 2026-02-25

tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy

Not yet recruitingNCT07433023

Shirley Ryan AbilityLabCerebral Palsy

Start: 2026-03-01End: 2029-01-01Target: 80Updated: 2026-02-25

Unknown Phase

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

CompletedNCT00660400

H. Lee Moffitt Cancer Center and Research InstituteLeukemia

Start: 2008-03-31End: 2014-06-30Updated: 2014-09-22

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

WithdrawnNCT04296214

Grupo Cooperativo de Hemopatías MalignasAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2020-01-01End: 2022-03-15Updated: 2021-07-09

Related Papers

Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.

2024-09-1417 citations

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

Blood2022-11-153 citations

445 Trial in progress: A phase 1b/2 study of alrizomadlin (APG-115), alone or combined with 5-azacitidine, in patients with relapsed/refractory acute myeloid leukemia (R/R AML)

Regular and Young Investigator Award Abstracts2021-11-01

Abstract CT160: The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma

Cancer Research2020-08-154 citations

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Blood2019-11-1341 citations

Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.

2014-02-1518 citations